Trending Stock News

Neos Therapeutics, Inc. (NEOS) Reaches $9.10 After 5.00% Down Move; Nuveen Texas Quality Income Municipal Fund (NTX) Sentiment Is 0.57

The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) is a huge mover today! The stock decreased 1.62% or $0.15 during the last trading session, reaching $9.1. About 205,317 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has risen 9.07% since February 20, 2017 and is uptrending. It has underperformed by 7.63% the S&P500.The move comes after 9 months negative chart setup for the $263.87M company. It was reported on Feb, 20 by Barchart.com. We have $8.65 PT which if reached, will make NASDAQ:NEOS worth $13.19 million less.

The stock decreased 0.18% or $0.0242 during the last trading session, reaching $13.4858. About 6,664 shares traded. Nuveen Texas Quality Municipal Income Fund (NTX) has declined 4.02% since February 20, 2017 and is downtrending. It has underperformed by 20.72% the S&P500.

Fruth Investment Management holds 0.12% of its portfolio in Nuveen Texas Quality Municipal Income Fund for 17,300 shares. Acg Wealth owns 33,621 shares or 0.09% of their US portfolio. Moreover, Whittier Trust Co Of Nevada Inc has 0.05% invested in the company for 38,666 shares. The California-based Whittier Trust Co has invested 0.01% in the stock. Advisory Services Network Llc, a Georgia-based fund reported 113 shares.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $263.87 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

Analysts await Neos Therapeutics, Inc. (NASDAQ:NEOS) to report earnings on March, 13. They expect $-0.60 earnings per share, up 47.37% or $0.54 from last year’s $-1.14 per share. After $-0.58 actual earnings per share reported by Neos Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3.45% negative EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *